-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155

Benzinga·05/07/2025 17:37:14
Listen to the news
Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $167 to $155.